Enlarged cardiophrenic lymph nodes predict disease involvement of the upper abdomen and the outcome of primary surgical debulking in advanced ovarian cancer

被引:23
|
作者
Luger, Anna K. [1 ]
Steinkohl, Fabian [1 ]
Aigner, Friedrich [1 ]
Jaschke, Werner [1 ]
Marth, Christian [2 ]
Zeimet, Alain G. [2 ]
Reimer, Daniel [2 ]
机构
[1] Innsbruck Med Univ, Dept Radiol, Innsbruck, Austria
[2] Innsbruck Med Univ, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria
关键词
cardiophrenic lymph node; ovarian cancer; predictive value; prognostic impact; residual disease; PERITONEAL CARCINOMATOSIS; PROGNOSTIC-SIGNIFICANCE; EXPLORATORY ANALYSIS; STAGE-III; LYMPHADENECTOMY; METASTASIS; RESECTION; TRIAL;
D O I
10.1111/aogs.13835
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction The outcome of ovarian cancer patients is highly dependent on the success of primary debulking surgery in terms of postoperative residual disease. This study critically evaluates the clinical impact of preoperative radiologic assessment of the cardiophrenic lymph node (CPLN) status in advanced ovarian cancer. Material and methods Baseline CT scans of 178 stage III and IV ovarian cancer patients were retrospectively reviewed by two independent radiologists. CPLN enlargement defined at a short-axis >= 5 mm was evaluated for its prognostic value and predictive power of upper abdominal tumor involvement and the chance of complete intra-abdominal tumor resection at primary debulking surgery. Only patients without surgically removed CPLN were eligible for this study. Results Enlarged CPLNs were detected in 50% of patients and correlated with radiologically suspicious (P = .028) and histologically confirmed (P = .001) paraaortic lymph node metastases. CPLNs >= 5 mm were associated with high CA-125 levels at baseline and revealed independent prognostic relevance for progression-free survival (hazard ratio [HR] 2.14, 95% confidence interval [CI] 1.33-3.42) and overall survival (HR 2.18, 95% CI 1.16-4.08). Noteworthy, patients with enlarged CPLNs nonetheless benefit from complete intra-abdominal tumor debulking in terms of an improvement in progression-free survival (HR 0.60, 95% CI 0.38-0.94) and overall survival (HR 0.59, 95% CI 0.35-0.82). Enlarged CPLNs correctly predicted carcinomatosis of the upper abdomen in 94.6%. A predictive score of complete tumor debulking, termed CD-score, which integrates, beside a CPLN short axis <5 mm, an ascites volume <500 mL, and CA-125 levels <500 U/mL at baseline, correctly predicted complete intra-abdominal debulking in 100% of patients. Conclusions CPLNs >= 5 mm predict upper abdominal tumor involvement. The application of the CD-score predicted complete macroscopic tumor resection at primary surgery in all of the patients. Although, CPLN pathology suggests extra-abdominal disease, we consistently demonstrated that patients nonetheless benefit from complete intra-abdominal tumor resection.
引用
收藏
页码:1092 / 1099
页数:8
相关论文
共 50 条
  • [1] A SUBXIPHOID APPROACH TO THE RESECTION OF ENLARGED CARDIOPHRENIC LYMPH NODES IN PRIMARY TREATMENT OF ADVANCED OVARIAN CANCER
    Cowan, R.
    Dessources, K.
    Roche, K. Long
    Zivanovic, O.
    Gardner, G.
    Chi, D.
    Sonoda, Y.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A54 - A54
  • [2] SURGICAL MANAGEMENT OF CARDIOPHRENIC LYMPH NODES IN ADVANCED OVARIAN CANCER
    Prader, S.
    Harter, P.
    Grimm, C.
    Traut, A.
    Waltering, K.
    Alesina, P.
    Heikaus, S.
    Ataseven, B.
    Heitz, F.
    Schneider, S.
    du Bois, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1472 - 1472
  • [3] Clinical significance of enlarged cardiophrenic lymph nodes by CT in advanced ovarian cancer
    Song, Sisi
    Chen, Huizhu
    Ning, Gang
    Guo, Yingkun
    Li, Xuesheng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Cardiophrenic lymph nodes in advanced ovarian cancer
    Agusti, Nuria
    Bonaldo, Giulio
    Kahn, Ryan M.
    Rosati, Andrea
    Nachira, Dania
    Pan, Teresa L.
    Mburu, Anisa
    Kochiashvili, Gvantsa
    Paredes, Pilar
    Hsu, Heng-Cheng
    Davies-Oliveira, Jennifer
    Ramirez, Pedro T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (01) : 150 - 158
  • [5] Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer
    Prader, Sonia
    Harter, Philipp
    Grimm, Christoph
    Traut, Alexander
    Waltering, Kai-Uwe
    Alesina, Pier Francesco
    Heikaus, Sebastian
    Ataseven, Beyhan
    Heitz, Florian
    Schneider, Stephanie
    du Bois, Andreas
    GYNECOLOGIC ONCOLOGY, 2016, 141 (02) : 271 - 275
  • [6] Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival
    Mert, Ismail
    Kumar, Amanika
    Sheedy, Shannon P.
    Weaver, Amy L.
    McGree, Michaela E.
    Kim, Bohyun
    Cliby, William A.
    GYNECOLOGIC ONCOLOGY, 2018, 148 (01) : 68 - 73
  • [7] Transdiaphragmatic resection of enlarged cardiophrenic lymph node during interval debulking surgery for advanced ovarian cancer
    Addley, Susan
    Morotti, Matteo
    Pinelli, Ciro
    Majd, Hooman Soleymani
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 37
  • [8] Radiologically enlarged cardiophrenic lymph nodes and CA-125 in relation to diaphragmatic carcinomatosis, surgical outcome, and overall survival in advanced ovarian cancer
    Plana, Alba
    Talo, Robert
    Wallengren, Nils-Olof
    Pudaric, Sonja
    Sartor, Hanna
    Asp, Mihaela
    ACTA ONCOLOGICA, 2023, 62 (05) : 451 - 457
  • [9] Radiologically enlarged cardiophrenic lymph nodes and CA-125 in relation to diaphragmatic carcinomatosis, surgical outcome, and overall survival in advanced ovarian cancer
    Plana, Alba
    Talo, Robert
    Wallengren, Nils-Olof
    Pudaric, Sonja
    Sartor, Hanna
    Asp, Mihaela
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A294 - A295
  • [10] SUBXIPHOID APPROACH FOR THE RESECTION OF ENLARGED SUPRADIAPHRAGMATIC CARDIOPHRENIC LYMPH NODES DURING PRIMARY CYTOREDUCTION FOR ADVANCED OVARIAN CANCER: A CASE REPORT
    Tsolakidis, D.
    Zouzoulas, D.
    Pappas, P.
    Pavlidi, O.
    Bili, E.
    Grimbizis, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A530 - A531